NCT07768514Active, not recruitingPhase 2
Maxigesic for Postoperative Pain Control After Laparoscopic or Robotic Gastrectomy
Prospective Randomized Trial to Evaluate the Efficacy and Safety of Maxigesic Injection for Post-operative Pain Control in Patients Who Have Undergone Laparoscopic or Robotic Gastrectomy
Source: ClinicalTrials.gov · Last updated 17 Aug 2026
Brief summary (registry, in English)
This prospective, randomized, phase 4 clinical trial aims to evaluate the efficacy and safety of intravenous Maxigesic, a fixed-dose combination of acetaminophen and ibuprofen, for postoperative pain control in patients undergoing laparoscopic or robotic gastrectomy for gastric cancer. A total of 90 participants will be randomly assigned to receive either Maxigesic or intravenous acetaminophen. The primary objective is to compare postoperative pain control between the two groups using the sum of pain intensity differences over 72 hours (SPID72). Secondary outcomes include postoperative pain scores, opioid consumption, rescue analgesic use, antiemetic use, and safety outcomes.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (actual)
- First submitted
- 12 Aug 2026
- Start date
- 21 Nov 2025
- Primary completion date
- 8 Nov 2026
- Lead sponsor
- Seoul National University Bundang Hospital
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07768514
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 90
- From 21 Nov 2025 to the primary completion date, 8 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who require conversion to open surgery.
- Any contraindication to the use of the study medications according to the prescribing information.
Other illness
- Known hypersensitivity to any component of the study medications.
Other
- Patients who do not undergo laparoscopic or robotic gastrectomy.
- Women who are pregnant or breastfeeding, or who plan to become pregnant during the study period.
- Participants or their partners who do not agree to use a medically acceptable method of contraception during the study period.
Who the study is looking for
- Adults aged 19 years or older at the time of written informed consent.
- Patients scheduled to undergo laparoscopic or robotic gastrectomy for gastric cancer.
- American Society of Anesthesiologists (ASA) physical status class I to III.
- Patients who voluntarily decide to participate after receiving a detailed explanation of the study and provide written informed consent.
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Seoul National University Bundang Hospital Coordinator of this site? Confirm its status | Seongam | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.